Tags: Press release
Lonza announced today that the company has signed
an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19.
October 30, 2020
Sun Chemical released its 11th annual Corporate Sustainability Report for the year ending 2019.
October 28, 2020
Pilot Chemical Corp., through its subsidiary Mason Chemical Company, has secured acceptance from the Environmental Protection Agency (EPA) to add a SARS-CoV-2 claim, along with four new antimicrobial claims, to the label of its Maguard® 5626 product.
October 27, 2020
LBB Specialties announced that Charkit Chemical Company has signed a domestic territory-based representation agreement with Elé Corporation, based in Chicago, Illinois.
October 27, 2020
Pilot Chemical Corp. is pleased to announce that through its subsidiary Mason Chemical Company, it has received EPA acceptance to add an emerging viral pathogen claim to the labels of eight products from the company’s EPA-registered quaternary ammonium compound and active ingredient line, under its Maquat® and Maguard® brands.
October 1, 2020
The CJB companies (CJB Industries, Inc. and CJB Applied Technologies, LLC) have announced a cooperative venture with National FFA to benefit the companies who support National FFA as well as the National FFA itself.
September 30, 2020
With a tremendous emphasis on the safety of its employees and community, Manufacturers Chemicals, LLC is pleased to announce it has reached two million man hours without a lost-time incident as classified by the Occupational Safety and Health Administration (OSHA).
September 28, 2020
The Society of Chemical Manufacturers & Affiliates (SOCMA) is pleased to announce the addition of five more companies to the association, expanding the total number of new members to 16 in the first three quarters of 2020. SOCMA’s Board of Governors last week approved chemical manufacturer Sofix and service providers Anchin, New York Center for Innovation, POWER Engineers and Rockwell Automation.
September 23, 2020
Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper response called ‘cytokine storm,’ and Lonza today announced a strategic collaboration to expand the manufacturing capacity for lenzilumab, currently in Phase 3 clinical trials for COVID-19, in advance of potential Emergency Use Authorization in 2020 and subsequent commercialization.
September 16, 2020
Lonza and Sheba Medical Center announced the first patient has been treated at Sheba Medical Center with a CD19 CAR-T cell immunotherapy manufactured using Lonza’s Cocoon® Platform.
September 8, 2020
